Navigation

Kliniske forsøg

Benefit-Risk Assessment in Pharmaceutical Research and Development

Udgivet af Taylor & Francis Ltd

Bogdetaljer

  • Hæftet
  • 220 sider
  • Engelsk
ISBN 9780367576240
Om denne bog

Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview …

Se alle bogdetaljer →
Prissammenligning

Ingen boghandelspriser listet endnu

Denne titel er i vores bogkatalog. Butikstilbud vises her, når de er tilgængelige.

Betroet sælger:

Ingen boghandelstilbud lige nu.

Søg efter ISBN
Opdateret i dag

Boghandelspriser

Boghandel Titel Format ISBN Pris Lagerstatus Levering

Ingen boghandelstilbud endnu

Vi har titlen i kataloget. Priser vises her, når boghandlere lister den.

0.0
0 anmeldelser
5
0
4
0
3
0
2
0
1
0
0%
Anbefaler
0
Verificeret
Alle anmeldelser (0)

Ingen anmeldelser endnu

Skriv en anmeldelse

Valgfri - Kun brugt til verifikation
0 / 5000 tegn
Bogdetaljer
Forlag Taylor & Francis Ltd
Kategori Kliniske forsøg
ISBN-13 9780367576240
EAN 9780367576240
Format Hæftet
Sprog Engelsk
sider 220
Produktbeskrivelse
Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment.The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule’s journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies. The book also focuses on a molecule’s entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety.Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.

Prishistorik

Indlæser prishistorik...

Få prisalarm

Bliv underrettet, når prisen falder til dit ønskede beløb.